SAN DIEGO, May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences:
- Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9, 2016 at 2:30 p.m. ET
- JMP Securities Life Sciences Conference in New York City on Tuesday, June 21, 2016 at 11:30 a.m. ET
Live webcasts of both presentations will be available at http://ir.retrophin.com/events.cfm and archived replays will be accessible for up to 90 days from each presentation date.
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring clinical-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets, including RE-034, in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Chenodal®, Cholbam® and Thiola®.
Contact: Chris Cline, CFA Senior Director, Investor Relations 646-564-3680 IR@retrophin.com